• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

舒尼替尼致转移性肾细胞癌患者甲状腺萎缩的发生率及机制。

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.

机构信息

Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, North-15, West-7, Kitaku, Sapporo 060-8638, Japan.

出版信息

Br J Cancer. 2011 Jan 18;104(2):241-7. doi: 10.1038/sj.bjc.6606029. Epub 2010 Dec 14.

DOI:10.1038/sj.bjc.6606029
PMID:21157447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3031892/
Abstract

BACKGROUND

To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib.

METHODS

Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients.

RESULTS

The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of the patients in the high reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland.

CONCLUSION

Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells.

摘要

背景

为了阐明舒尼替尼引起甲状腺萎缩的发生率和机制,我们研究了转移性肾细胞癌患者接受舒尼替尼治疗后甲状腺的容积和功能的连续变化,并评估了甲状腺的组织学变化。

方法

在基线、治疗期间和治疗后期间,通过计算机断层扫描体积测量法测量甲状腺体积和甲状腺功能。对 4 例尸检患者的甲状腺进行组织学评估。

结果

在 17 例患者的最后一次评估中,甲状腺体积的中位数在舒尼替尼治疗期间的减少率为 30%。在高减少率组(n=8;体积减少超过 50%)中,甲状腺功能减退的发生率明显高于低减少率组(n=9;体积减少小于 50%)。高减少率组中有一半的患者在舒尼替尼治疗期间出现短暂的促甲状腺激素抑制,提示甲状腺毒症。组织学评估显示甲状腺滤泡萎缩和滤泡上皮细胞变性,而甲状腺内血管容积没有明显减少。

结论

舒尼替尼治疗后常观察到甲状腺萎缩,可能是由舒尼替尼诱导的甲状腺毒症或舒尼替尼的直接作用导致甲状腺滤泡细胞变性引起的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/e69b1387f194/6606029f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/000510ab9e9c/6606029f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/ff038fc8824f/6606029f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/01dceae6a4af/6606029f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/2cd2735369fd/6606029f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/e69b1387f194/6606029f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/000510ab9e9c/6606029f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/ff038fc8824f/6606029f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/01dceae6a4af/6606029f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/2cd2735369fd/6606029f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf9a/3031892/e69b1387f194/6606029f5.jpg

相似文献

1
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.舒尼替尼致转移性肾细胞癌患者甲状腺萎缩的发生率及机制。
Br J Cancer. 2011 Jan 18;104(2):241-7. doi: 10.1038/sj.bjc.6606029. Epub 2010 Dec 14.
2
A CT scan aspect of "hypodense thyroid gland" after sunitinib treatment for metastatic carcinoma of the kidney.
J Clin Endocrinol Metab. 2011 Mar;96(3):590-1. doi: 10.1210/jc.2010-1519.
3
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.索拉非尼或舒尼替尼治疗后 CT 监测肾细胞癌患者甲状腺大小变化:与甲状腺功能的比较。
Eur J Radiol. 2012 Sep;81(9):2060-5. doi: 10.1016/j.ejrad.2011.06.035. Epub 2011 Jul 2.
4
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?转移性癌患者接受舒尼替尼治疗后出现甲状腺功能障碍:是否涉及甲状腺自身免疫?
Thyroid. 2015 Nov;25(11):1255-61. doi: 10.1089/thy.2015.0170. Epub 2015 Oct 14.
5
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.舒尼替尼治疗日本肾细胞癌患者引起的甲状腺异常的临床特征。
Endocr J. 2010;57(10):873-80. doi: 10.1507/endocrj.k10e-130. Epub 2010 Aug 21.
6
Sunitinib induces hypothyroidism with a markedly reduced vascularity.舒尼替尼可导致甲状腺功能减退症,并显著降低血管生成。
Thyroid. 2010 Mar;20(3):323-6. doi: 10.1089/thy.2009.0414.
7
Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?舒尼替尼治疗肾细胞癌患者甲状腺体积缩小:甲状腺功能不可逆性损伤的潜在标志物?
Thyroid. 2010 Mar;20(3):317-22. doi: 10.1089/thy.2009.0125.
8
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?服用苹果酸舒尼替尼的转移性肾细胞癌患者中的高脂血症和甲状腺功能减退。相关还是不相关的不良事件?
Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009. Epub 2014 Sep 22.
9
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.酪氨酸激酶抑制剂(舒尼替尼、索拉非尼和阿昔替尼)治疗转移性肾细胞癌患者的甲状腺功能障碍。
Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076. Epub 2012 May 23.
10
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?舒尼替尼诱导的甲状腺功能减退症是否在舒尼替尼治疗转移性肾细胞癌的活性中起作用?
Chemotherapy. 2012;58(3):200-5. doi: 10.1159/000337079. Epub 2012 Jun 29.

引用本文的文献

1
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.一项关于舒尼替尼的美国食品药品监督管理局不良事件报告系统(FAERS)事件的真实世界药物警戒研究。
Front Pharmacol. 2024 Jul 24;15:1407709. doi: 10.3389/fphar.2024.1407709. eCollection 2024.
2
Relationship between Thyroid CT Density, Volume, and Future TSH Elevation: A 5-Year Follow-Up Study.甲状腺CT密度、体积与未来促甲状腺激素升高之间的关系:一项5年随访研究。
Life (Basel). 2023 Dec 6;13(12):2303. doi: 10.3390/life13122303.
3
Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series.

本文引用的文献

1
Sunitinib induces hypothyroidism with a markedly reduced vascularity.舒尼替尼可导致甲状腺功能减退症,并显著降低血管生成。
Thyroid. 2010 Mar;20(3):323-6. doi: 10.1089/thy.2009.0414.
2
Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?舒尼替尼治疗肾细胞癌患者甲状腺体积缩小:甲状腺功能不可逆性损伤的潜在标志物?
Thyroid. 2010 Mar;20(3):317-22. doi: 10.1089/thy.2009.0125.
3
Rapid estimation of split renal function in kidney donors using software developed for computed tomographic renal volumetry.
先前基于抗血管生成酪氨酸激酶抑制剂的治疗作为转移性肾细胞癌患者中纳武单抗介导的复发性甲状腺疾病不良事件的潜在诱发因素:病例系列
Biomedicines. 2023 Nov 4;11(11):2974. doi: 10.3390/biomedicines11112974.
4
Hypothyroidism after radiation exposure: brief narrative review.辐射暴露后甲状腺功能减退症:简要叙述性综述。
J Neural Transm (Vienna). 2020 Nov;127(11):1455-1466. doi: 10.1007/s00702-020-02260-5. Epub 2020 Oct 9.
5
Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.舒尼替尼作为阿拉伯人群转移性肾细胞癌患者一线治疗的疗效及预后因素
JCO Glob Oncol. 2020 Feb;6:19-26. doi: 10.1200/JGO.19.00111.
6
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma.厌食、高血压、气胸和甲状腺功能减退:阿帕替尼治疗晚期骨肉瘤后临床结局改善的潜在迹象。
Cancer Manag Res. 2020 Jan 7;12:91-102. doi: 10.2147/CMAR.S232823. eCollection 2020.
7
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.转移性肾细胞癌患者在舒尼替尼2/1交替给药方案期间的甲状腺功能指标
Endocrine. 2020 Mar;67(3):597-604. doi: 10.1007/s12020-019-02088-4. Epub 2019 Nov 2.
8
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.舒尼替尼所致甲状腺功能减退对转移性肾细胞癌患者生存的影响。
BMC Cancer. 2019 Apr 30;19(1):407. doi: 10.1186/s12885-019-5610-8.
9
Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies.甲状腺激素与癌症:临床前和临床研究的全面综述
Front Endocrinol (Lausanne). 2019 Feb 13;10:59. doi: 10.3389/fendo.2019.00059. eCollection 2019.
10
Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study.索拉非尼引起的前列腺体积缩小:一种通过影像学检测到的新不良反应——一项初步研究
J Belg Soc Radiol. 2018 Oct 26;102(1):69. doi: 10.5334/jbsr.1607.
利用为计算机断层扫描肾容积测量开发的软件快速估计供肾者的分肾功能。
Eur J Radiol. 2011 Jul;79(1):15-20. doi: 10.1016/j.ejrad.2009.11.013. Epub 2009 Dec 5.
4
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.一项舒尼替尼治疗日本转移性肾细胞癌患者的 II 期研究:对治疗、疗效和安全性的深入了解。
Jpn J Clin Oncol. 2010 Mar;40(3):194-202. doi: 10.1093/jjco/hyp146. Epub 2009 Nov 7.
5
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.舒尼替尼在胃肠道间质瘤和肾癌中的获益-风险评估。
Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003.
6
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌患者的总生存期及更新结果比较
J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.
7
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.舒尼替尼诱发甲状腺功能减退的临床意义:一项前瞻性评估。
Br J Cancer. 2008 Aug 5;99(3):448-54. doi: 10.1038/sj.bjc.6604497.
8
Effect of sunitinib on growth and function of FRTL-5 thyroid cells.
Thyroid. 2008 Jun;18(6):631-5. doi: 10.1089/thy.2007.0336.
9
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.一种新型酪氨酸激酶选择性抑制剂舒尼替尼通过阻断碘摄取诱导短暂性甲状腺功能减退。
J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4. doi: 10.1210/jc.2007-0586. Epub 2007 Jun 26.
10
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.